Ernexa Therapeutics Inc. Revenue, Remaining Performance Obligation, Percentage
Ernexa Therapeutics Inc. (ERNA) had Revenue, Remaining Performance Obligation, Percentage of 100.00% as of 2024-09-30, per its 10-Q filed 2024-11-12.
Financial Statements › Notes › Revenue from Contract with Customer
us-gaap:RevenueRemainingPerformanceObligationPercentage · last filed 2025-03-12
- 2024-09-30: Revenue, Remaining Performance Obligation, Percentage 100.00%.
- 2024-09-24: Revenue, Remaining Performance Obligation, Percentage 100.00%.
- 2024-06-30: Revenue, Remaining Performance Obligation, Percentage 100.00%.
- 2023-02-21: Revenue, Remaining Performance Obligation, Percentage 100.00%.
| Period end | Revenue, Remaining Performance Obligation, Percentage |
|---|---|
| 2024-09-30 | 100.00% 10-Q · filed 2024-11-12 |
| 2024-09-24 | 100.00% 10-K · filed 2025-03-12 |
| 2024-06-30 | 100.00% 10-Q · filed 2024-08-13 |
| 2023-02-21 | 100.00% 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |